JPRN-UMIN000009084已完成未知
Study to evaluate the bi-weekly schedule of eribulin for patients with advanced or reccurent breast cancer - Study to evaluate the bi-weekly schedule of eribulin for patients with advanced or reccurent breast cancer
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Systemic infection 2)Dirrea, ileus 3)GI bleeding 4)Sever drug allergy 5)Sever renal and/or liver disfunction 6)Significant interstitial pneumonia or plumonary fibrosis by chest X-P 7)Pleural effusion, peritoneal effusion 8)Uncontrolled hypertension or diabetes mellitus 9)Maintenance therapy with systemic corticosteroids 10)Pregnant women or women with suspected pregnancy 11)Active double cancer 12)Severe psychiatric disorder 13)Active brain metastases 14)Participating in other chemotherapy or study 15) Judeged by the investigator to be unfit for this study
研究者
相似试验
已完成
2 期
Phase II study of Eribulin every other week maintenance therapy, after induction therapy of Eribulin on day1 and 8 for 3 cycles, in patients with hormone receptor positive and HER2-negative advanced recurrent breast cancer.JPRN-UMIN000013928onprofit Organization Japan Clinical Cancer Research Organization60
招募中
不适用
Feasibility study of the bi-weekly administration of eribulin for metastatic breast cancerMetastatic breast cancerJPRN-UMIN000013596Saitama Medical University International Medical Center40
招募中
2 期
A phase II study of biweekly Docetaxel + Nedaplatin in advanced esophageal cancer in patients previously treated with FP and anti-PD-1 antibodiesEsophageal cancerJPRN-jRCTs061210089agano Hiroaki18
终止
4 期
Treatment of clozapine associated obesity and diabetes with exenatide in people with schizophreniaTreatment resistant schizophreniaMetabolic and Endocrine - DiabetesMental Health - SchizophreniaDiet and Nutrition - ObesityobesitydiabetesACTRN12615000524594The University of Queensland28
进行中（未招募）
不适用
A randomized phase III studyComparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel (dtEC -- dtT)(A-arm) versus three weekly epirubicin + cyclophosphamide, 5-fluorouracil followed by docetaxel (FEC -- T)(B-arm) in lymph node positive or high risk lymph node negative breast cancer patients- a continuation of the feasibility part of the SBG 2004-1 study - PANTHERymph node positive or high risk lymph node negative breast cancer patients.MedDRA version: 16.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-002061-12-DESBG2,000